– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Connext, a clinical stage biotechnology company, announced the ...
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the ...
Please provide your email address to receive an email when new articles are posted on . The phase 2 trial assessed tolerability of abemaciclib (Verzenio, Eli Lilly & Co.) dose escalation among ...
BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma Early-phase clinical trials (EPCTs) have been ...
Evaluating the correlation between clonal hematopoiesis and response to regorafenib and nivolumab in patients with refractory metastatic colorectal cancer. KEYSTEP-008: Pembrolizumab (pembro)-based ...
PALO ALTO, CA / ACCESS Newswire / May 30, 2025 / Riboscience, LLC, today announced the presentation of data from the completed dose escalation Phase 1a of the Phase 1a/b clinical trial of the ENPP1 ...
CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer ...
Perspective Therapeutics (CATX) announced initial results from its ongoing Phase 1/2a clinical trial of VMT-alpha-NET that are being presented at the 2024 North American Neuroendocrine Tumor Society ...
LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation ("Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results